In anticipation of a national shortage of hospital pharmacists, job postings increased by more than 12% in the first three months of 2024 compared to the first quarter of 2023. 

Select Walgreens pharmacies will host Boehringer Ingelheim's clinical trials, with a focus on recruiting people who are obese, overweight or have Type 2 diabetes, Walgreens said May 2. 

Emergent BioSolutions is consolidating operations, closing two manufacturing plants and laying off about 300 employees, the Maryland-based drugmaker said May 1. 

Louisville, Ky.-based ScionHealth will begin purchasing certain bulk drugs from Mark Cuban's Cost Plus Drug Co., the 94-hospital system said May 1. This marks Cost Plus Drugs' second health system partnership. 

The Federal Trade Commission sent letters to 10 drugmakers April 30 warning them that hundreds of patent listings for 20 drugs are invalid. The agency said "junk" listings keep drug prices high by stalling generic competition. 

Amazon's first-quarter earnings increased 225% in 2024 compared to last year, and the company listed its pharmacy services as one of its recent wins. 

Franklin, Tenn.-based Community Health Systems was the first health system to partner with and buy medicines manufactured by Mark Cuban Cost Plus Drug Co., and expects the partnership to result in significant advantages for its hospitals.

 The FDA has granted full approval for Pfizer's Tivdak (tisotumab vedotin-tftv) to treat cervical cancer in patients whose disease has progressed on or after chemotherapy. 

California's drug label, CalRx, is teaming up with Amneal Pharmaceuticals to offer naloxone at a 40% discount, Gov. Gavin Newsom said April 29.

Pfizer's first FDA-approved gene therapy is one of the most expensive medications in the U.S.